Previous Articles

Kythera Newsroom

KYTHERA has named Joseph L. Turner to its Board of Directors

February 14, 2008

LOS ANGELES, February 14, 2008 – Kythera Biopharmaceuticals, Inc. ("Kythera") has named Joseph L. Turner to its Board of Directors effective January 23, 2008. Turner also has been appointed to serve as Chairman of Kythera’s Audit Committee.

Joseph Turner joins Kythera’s Board with more than 25 years of financial management experience in pharmaceutical and biotech industries worldwide. As Chief Financial Officer of several early stage industrial companies, Turner was responsible for eight equity offerings, including three Initial Public Offerings (IPOs), raising a total of $450 million in the public and private markets. He spent seven years as Chief Financial Officer at Myogen, Inc. where he led two private and three public rounds of financing and was a key player in the negotiation of the $2.5 billion sale of the company to Gilead Sciences in 2006. Prior to Myogen, Turner was Vice President of Finance at Cortech, Inc. where he led the transition from a private concern to a public company and successfully completed both IPO and follow-on offerings. Other financial leadership roles include Director of Finance, Eli Lilly and Company (Switzerland); Treasurer, Eli Lilly and Company (Switzerland); and Vice President of Finance, Centaur Pharmaceuticals. He is member of the Board of Directors of Sequel Pharmaceuticals and of SGX Pharmaceuticals and is a former board member and Chairman of the Audit Committee of NovaCardia, Inc.

Turner holds a BA in Chemistry from Swarthmore College; an MA in Molecular Biology from the University of Colorado at Boulder; and an MBA from University of North Carolina at Chapel Hill.

“Joe’s extensive background in strategic planning, organizational development, investment banking and investor relations combined with his significant experience and knowledge of securities laws makes him exceptionally qualified to serve as a member of our board and chairman of our audit committee,” stated Keith Leonard, President and Chief Executive Officer of Kythera. “We look forward to leveraging his industry expertise and perspective as we move into Kythera’s next round of funding and prepare for access to public markets.”

Turner joins existing board members, Camille Samuels, managing director, Versant Ventures; Nathaniel E. David, PhD, co-founder and chief science officer, Kythera; Keith Leonard, co-founder, president and chief executive officer, Kythera; Dennis Fenton, former executive vice president, operations, Amgen; Robert Nelsen, managing director, ARCH Venture Partners; and David Schnell, MD, managing director, Prospect Venture Partners.